The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $3.78 in the prior trading day, Anavex Life Sciences Corporation (NASDAQ: AVXL) closed at $3.68, down -2.65%. In other words, the price has decreased by $-2.65 from its previous closing price. On the day, 1.08 million shares were traded. AVXL stock price reached its highest trading level at $3.85 during the session, while it also had its lowest trading level at $3.64.
Ratios:
Our goal is to gain a better understanding of AVXL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.85 and its Current Ratio is at 11.85. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Cantor Fitzgerald on December 06, 2022, Downgraded its rating to Neutral and sets its target price to $11 from $16 previously.
On June 23, 2022, Berenberg started tracking the stock assigning a Buy rating and target price of $40.
On September 23, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $35.BTIG Research initiated its Buy rating on September 23, 2021, with a $35 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 28 ’24 when MISSLING CHRISTOPHER U sold 73,380 shares for $5.11 per share. The transaction valued at 374,972 led to the insider holds 1,250,210 shares of the business.
MISSLING CHRISTOPHER U sold 268,000 shares of AVXL for $2,139,310 on Jun 28 ’23. The President and CEO now owns 1,018,210 shares after completing the transaction at $7.98 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVXL now has a Market Capitalization of 302173984 and an Enterprise Value of 166620288.
Stock Price History:
The Beta on a monthly basis for AVXL is 0.66, which has changed by -0.51847136 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, AVXL has reached a high of $10.45, while it has fallen to a 52-week low of $3.60. The 50-Day Moving Average of the stock is -25.71%, while the 200-Day Moving Average is calculated to be -44.56%.
Shares Statistics:
The stock has traded on average 1.28M shares per day over the past 3-months and 1260340 shares per day over the last 10 days, according to various share statistics. A total of 82.07M shares are outstanding, with a floating share count of 79.52M. Insiders hold about 3.16% of the company’s shares, while institutions hold 31.71% stake in the company. Shares short for AVXL as of 1711584000 were 22117935 with a Short Ratio of 17.31, compared to 1709164800 on 20019988. Therefore, it implies a Short% of Shares Outstanding of 22117935 and a Short% of Float of 27.82.
Earnings Estimates
Anavex Life Sciences Corporation (AVXL) is currently under the scrutiny of Anavex Life Sciences Corp. analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $17.30, with high estimates of $469.10 and low estimates of $7.22.
